Retevmo vs. Gavreto
Are Retevmo and Gavreto the Same Thing?
Retevmo (selpercatinib) and Gavreto (pralsetinib) are kinase inhibitors used to treat adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
Retevmo is also used to treat adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Side effects of Retevmo and Gavreto that are similar include increased alanine aminotransferase (ALT), decreased calcium, dry mouth, decreased sodium, diarrhea, fatigue, fluid retention (edema), high blood pressure (hypertension), and constipation.
Side effects of Retevmo that are different from Gavreto include increased aspartate aminotransferase (AST), increased blood sugar (glucose), decreased leukocytes, decreased albumin, increased creatinine, increased alkaline phosphatase, decreased platelets, increased total cholesterol, and rash.
Side effects of Gavreto that are different from Retevmo include musculoskeletal pain, fever, cough, pneumonia, decreased lymphocytes, decreased neutrophils, decreased phosphate, and decreased hemoglobin.
Both Retevmo and Gavreto may interact with strong and moderate CYP3A inhibitors or inducers.
Retevmo may also interact with acid-reducing agents (such as proton pump inhibitors, H2 receptor antagonists, and locally-acting antacids), CYP2C8 and CYP3A substrates, and medications known to prolong the QT interval.
Gavreto may also interact with combined P-gp and strong CYP3A inhibitors.
What Are Possible Side Effects of Retevmo?
Common side effects of Retevmo include:
- increased aspartate aminotransferase (AST),
- increased alanine aminotransferase (ALT),
- increased blood sugar (glucose),
- decreased leukocytes,
- decreased albumin,
- decreased calcium,
- dry mouth,
- diarrhea,
- increased creatinine,
- increased alkaline phosphatase,
- high blood pressure (hypertension),
- fatigue,
- fluid retention (edema),
- decreased platelets,
- increased total cholesterol,
- rash,
- decreased sodium, and
- constipation
What Are Possible Side Effects of Gavreto?
Common side effects of Gavreto include:
- fatigue,
- constipation,
- musculoskeletal pain,
- high blood pressure (hypertension),
- fever,
- fluid retention (edema),
- diarrhea,
- dry mouth,
- cough,
- pneumonia,
- decreased lymphocytes,
- decreased neutrophils,
- decreased phosphate,
- decreased hemoglobin,
- decreased sodium,
- decreased calcium, and
- increased alanine aminotransferase (alt)
What Is Retevmo?
Retevmo (selpercatinib) is a kinase inhibitor used to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
What Is Gavreto?
Gavreto (pralsetinib) is a kinase inhibitor used to treat adult patients with metastatic rearranged during transfection (RET), fusion-positive, non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
What Drugs Interact With Retevmo?
Retevmo may interact with other medicines such as:
- acid-reducing agents (such as proton pump inhibitors, H2 receptor antagonists, and locally-acting antacids),
- strong and moderate CYP3A inhibitors or inducers,
- CYP2C8 and CYP3A substrates, and
- medications known to prolong the QT interval
What Drugs Interact With Gavreto?
Gavreto may interact with other medicines such as:
- strong CYP3A inhibitors,
- combined P-gp and strong CYP3A inhibitors, and
- strong CYP3A inducers
Tell your doctor all medications and supplements you use.
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.